Modality
ASO
MOA
HER2
Target
JAK2
Pathway
JAK/STAT
RBLN
Development Pipeline
Preclinical
~Oct 2011
→ ~Jan 2013
Phase 1
~Apr 2013
→ ~Jul 2014
Phase 2
~Oct 2014
→ ~Jan 2016
Phase 3
~Apr 2016
→ ~Jul 2017
NDA/BLA
Oct 2017
→ Mar 2027
NDA/BLACurrent
NCT03513961
1,383 pts·LN
2020-10→2026-09·Completed
NCT04132570
1,056 pts·LN
2017-10→2027-03·Recruiting
2,439 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-09-145mo awayPh3 Readout· LN
2027-03-0811mo awayPh3 Readout· LN
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
NDA/BLA
Recruit…
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2026-09-14 · 5mo away
LN
Ph3 Readout
2027-03-08 · 11mo away
LN
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03513961 | NDA/BLA | LN | Completed | 1383 | EASI-75 |
| NCT04132570 | NDA/BLA | LN | Recruiting | 1056 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| Voxaderotide | Viking Therapeutics | Approved | PD-L1 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 |